Therapy for hard-to-treat non-Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests a treatment (called CIK) for people with non-Hodgkin lymphoma that has not responded well to regular chemotherapy. If standard chemotherapy isn’t working anymore, this trial may offer another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-Hodgkin lymphoma that has not responded well to regular chemotherapy
- Your doctor must say you need additional treatment
- You must be willing to take part in the study treatment
- You must be able to tolerate the study treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
This Phase 2 trial studies whether CIK therapy can help people with stages I–III esophageal cancer after they finish chemotherapy. It looks at safety and possible benefits, especially in people whose body and organs are working well.
This trial tests whether giving immune cells called CIK cells can help prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have had their tumor removed and are currently cancer-free.
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
This study tests a type of immune-cell therapy (cytokine-induced killer cells) for people with certain grade 1–2 aggressive brain tumors that have already been treated with radiation and temozolomide. It aims to see whether the treatment can control the tumor and be tolerated safely.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.